Metered-Dose Inhalers to Be Phased Out

Metered-Dose Inhalers to Be Phased Out



www.PuffMinder.com


Read FULL STORY in Modern Medicine


Seven (7) metered-dose inhalers that contain ozone-depleting chlorofluorocarbons will be gradually removed from the U.S. marketplace, according to an April 13 announcement by the U.S. Food and Drug Administration.

The inhalers are used to treat asthma and chronic obstruction pulmonary disease. The affected products and their last date to be manufactured, sold or dispensed in the United States are: Tilade Inhaler (nedocromil), June 14, 2010; Alupent Inhalation Aerosol (metaproterenol), June 14, 2010; Azmacort Inhalation Aerosol (triamcinolone), Dec. 31, 2010; Intal Inhaler (cromolyn), Dec. 31, 2010; Aerobid Inhaler System (flunisolide), June 30, 2011; Combivent Inhalation Aerosol (albuterol and ipratropium in combination), Dec. 31, 2013; Maxair Autohaler (pirbuterol), Dec. 31, 2013.
Scroll to top